governmentFilingsNewsغير مصنف

BRIEF-Sanofi and Regeneron accepted for priority review by U.S. FDA

* Sanofi and Regeneron announce dupilumab biologics
license application accepted for priority review by U.S. FDA

Source text for Eikon:
Further company coverage:

(Gdynia Newsroom)

اظهر المزيد

مقالات ذات صلة

زر الذهاب إلى الأعلى